Portfolio

PregLem SA
Pharmaceuticals
Switzerland
www.preglem.com

PregLem SA was a specialty biopharmaceutical company focused on developing and commercializing a portfolio of innovative products addressing significant benign gynecological conditions and infertility.

The company's assets were products at preclinical and clinical stages of development that were spun-off from Ipsen Pharma SA and licensed from HRA Pharma SA.

In 2010 PregLem SA was acquired for total cash considerations of up to CHF445 million by Gedeon Richter, Hungary’s largest drugmaker (RICHT:HB).


Status: Realised

Contact person: Claudio Nessi



Back to our portfolio

Investment

NeoMed identified PregLem SA as an attractive investment opportunity in 2007 and had early access to the opportunity through personal contacts with the company’s CEO and network in the venture capital industry in Europe.

NeoMed participated in the Series A financing. As a board director NeoMed supported the company in the recruitment of key employees and independant board members, in the licensing of products from Ipsen and HRA Pharma SA and finally in the successful trade sale of the company to Gedeon Richter plc.

NeoMed sold its shares in the trade sale in 2010.